- CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off?
- Five impactful biotech companies to know in New York
- Protecting privacy across borders: Is strategic outsourcing the answer to data protection compliance in clinical research?
- PIPEs in biotech fundraising: is this growing trend fueled by economic uncertainty here to stay?
- Illumina: DNA giant in troubled waters
- Beyond Biotech podcast 65 – Disease X and pandemic preparedness
- Obesity drug success sparks biotech buying spree
- Tackling the skilled labor shortage in biopharma manufacturing
- Eight anti-aging startups on a mission to extend lives
- Unlocking the potential of cell and gene therapies
- Base editing hits the clinic in the U.S.
- U.S. approval for psychedelic drug MDMA nears after success in clinic
- Beyond Biotech podcast 64 – Precision immuno-oncology therapies
- Recent advancements in prostate cancer research over the past year
- The next frontier in genomic technologies for rare diseases